Please assess the completion status of the following clinical trial:

Trial Title: Glycemic Effect of Colesevelam HCl (Welchol) in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects ≥18 and ≤75 years of age~* Clinical diagnosis of type 2 diabetes~* Currently treated with metformin, a sulfonylurea, or combination metformin/sulfonylurea; stable dose for ≥3 months~* HbA1c of 7.0-9.0% inclusive~* If taking lipid lowering medications, stable dose for \>30 days~Exclusion Criteria:~* Taken oral or injected prednisone or cortisone medications in the previous 30 days. (Topical or inhaled steroids will not be considered excluded medications.)~* Current use of insulin or TZD's, or incretins~* LDL \<70 mg/dL~* Serum triglycerides \>500 mg/dL~* History of hypertriglyceridemia-induced pancreatitis~* History of gastrointestinal disorder such as dysphagia, swallowing disorder, intestinal motility disorder or prior bowel obstruction~* History or presence of any severe medical or psychological condition or chronic conditions/infections that in the opinion of the Investigator would compromise the subject's safety or successful participation in the study~* Unable to follow the study protocol~* Unable to speak, read and write in English~* Pregnant, planning to become pregnant, breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Welchol then Placebo (Type: PLACEBO_COMPARATOR): 3.75 grams of colesevelam HCl (Welchol) at evening meal for 12 weeks, and then crossover to placebo at evening meal for 12 weeks.
- Placebo then Welchol (Type: PLACEBO_COMPARATOR): Placebo taken for 12 weeks at evening meal, and then crossover to 3.75 grams of colesevelam HCl taken at evening meal fro 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).